StreetInsider.com News Articles

Can-Fite pancreatic cancer drug data accepted for ESMO 2026 presentation

Mon, 20 Jul 2026 07:00:18 -0400

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) announced that an abstract from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026.

The abstract, titled "Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study," covers a study of oral Namodenoson in patients with advanced pancreatic cancer who had progressed following prior standard therapies. According to the company, the study met its primary safety endpoint and showed survival outcomes along with disease stabilization. One patient

Can-Fite pancreatic cancer drug data accepted for ESMO 2026 presentation

Mon, 20 Jul 2026 07:00:18 -0400

Can-Fite pancreatic cancer drug data accepted for ESMO 2026 presentation

Mon, 20 Jul 2026 07:00:18 -0400

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite receives Japanese patent allowance for Namodenoson obesity use

Fri, 26 Jun 2026 07:01:04 -0400

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that the Japan Patent Office has allowed Japanese Patent Application No. 2025-049941, a divisional application covering the use of A3 adenosine receptor agonists, including its drug candidate Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders.

The company states it has previously secured patent protection for this technology in the United States, Canada, Australia, and Israel. The Japanese allowance adds to that portfolio in a market the company describes as one of the world's largest for pharmaceuticals.

Namodenoson is an oral drug candidate that selectively targets the A3 adenosine receptor. The company

Can-Fite receives Japanese patent allowance for Namodenoson obesity use

Fri, 26 Jun 2026 07:01:04 -0400

Namodenoson is an oral drug candidate that selectively targets the A3 adenosine receptor. The company

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Fri, 26 Jun 2026 07:00:00 -0400